What does this research mean for the field?

Combined genetic and genomic testing strategies are more effective and cost-effective compared to no testing for guiding treatment decisions in HR+/HER2– breast cancer patients in the US. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To evaluate the effectiveness and cost-effectiveness of genetic and genomic testing in guiding treatment for HR+/HER2– breast cancer.

February 22, 2026Open Access

Clinical and economic benefits of combined genetic and genomic testing strategies to guide treatment decisions for patients with HR+/HER2– breast cancer in the US

Key Points

To evaluate the effectiveness and cost-effectiveness of genetic and genomic testing in guiding treatment for HR+/HER2– breast cancer.
Comparison of testing strategies (full testing vs. no testing)
Analysis of cost-effectiveness based on survival and quality-of-life outcomes
Focus on the population with HR+/HER2– breast cancer
Full testing strategy showed increased effectiveness compared to no testing
Cost-effective outcomes were achieved with the full testing strategy
Supporting improved survival and quality of life for women with breast cancer

Abstract

Compared to no testing, the full testing strategy of genetic and genomic testing was more effective at a lower cost or was cost-effective, supporting the goal to increase the survival and the quality-of-life of women with breast cancer along the cancer care continuum.

Clinical and economic benefits of combined genetic and genomic testing strategies to guide treatment decisions for patients with HR+/HER2– breast cancer in the US

Key Points

Abstract

Cite This Study